FIXX Stock Overview
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.
Homology Medicines, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.40|
|52 Week High||US$5.15|
|52 Week Low||US$1.30|
|1 Month Change||-2.78%|
|3 Month Change||-35.78%|
|1 Year Change||-71.89%|
|3 Year Change||-92.97%|
|5 Year Change||n/a|
|Change since IPO||-92.50%|
Recent News & Updates
Here's Why We're Watching Homology Medicines' (NASDAQ:FIXX) Cash Burn SituationJan 28
We Think Homology Medicines (NASDAQ:FIXX) Can Afford To Drive Business GrowthSep 18
Growth Investors: Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 20%Aug 14
Industry Analysts Just Made A Sizeable Upgrade To Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue ForecastsMay 22
Homology Medicines (NASDAQ:FIXX) Is In A Good Position To Deliver On Growth PlansApr 17
Are Institutions Heavily Invested In Homology Medicines, Inc.'s (NASDAQ:FIXX) Shares?Mar 13
Homology Medicines' (NASDAQ:FIXX) Stock Price Has Reduced 25% In The Past YearFeb 03
|FIXX||US Biotechs||US Market|
Return vs Industry: FIXX underperformed the US Biotechs industry which returned -11.2% over the past year.
Return vs Market: FIXX underperformed the US Market which returned -20.6% over the past year.
|FIXX Average Weekly Movement||10.7%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: FIXX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: FIXX's weekly volatility (11%) has been stable over the past year.
About the Company
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company’s various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye.
Homology Medicines, Inc. Fundamentals Summary
|FIXX fundamental statistics|
Is FIXX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|FIXX income statement (TTM)|
|Cost of Revenue||US$94.85m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.075|
|Net Profit Margin||-133.82%|
How did FIXX perform over the long term?See historical performance and comparison